Memantine Zydus France

Memantine, the active ingredient in Memantine Zydus France, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is used for symptomatic treatment of Alzheimer’s disease in adults.

GNH USA supplies Memantine Zydus France as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine is indicated for the symptomatic management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and function. - Alzheimer’s disease (mild to moderate): may help maintain cognitive performance and daily living activities. - Alzheimer’s disease (moderate to severe): may support functional abilities and reduce behavioral symptoms. - Alzheimer’s disease (early stage): may delay progression of memory loss and executive dysfunction.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: transient light‑headedness, especially after dose initiation. - Headache: mild to moderate intensity, often resolves with continued therapy. - Constipation: reduced bowel movements, may require dietary adjustment. - Confusion: occasional disorientation, typically early in treatment.

Serious or Rare Side Effects: - Seizures: rare but may occur, particularly in patients with pre‑existing seizure disorders. - Allergic reactions: rash, pruritus, or angioedema requiring medical attention. - Hallucinations: visual or auditory disturbances, usually reversible. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis, necessitating immediate discontinuation.

Before initiating memantine, consider the following safety measures. - Renal impairment: adjust dose or avoid use in severe renal dysfunction. - Hepatic impairment: monitor liver function tests and use with caution. - Concomitant NMDA antagonists: avoid co‑administration to reduce additive toxicity. - Blood pressure monitoring: watch for hypertension, especially in patients with cardiovascular disease. - Discontinuation: do not stop abruptly; taper under medical supervision to minimize withdrawal effects. - Store below 25°C: keep in the original pack, protect from moisture.

Memantine may interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism can increase neuropsychiatric adverse events. - Other NMDA antagonists (e.g., ketamine): additive risk of CNS effects. - Potassium‑sparing diuretics (e.g., spironolactone): may raise serum potassium when renal function is compromised.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may blunt cognitive benefits of memantine. - CNS depressants (e.g., benzodiazepines): monitor for enhanced sedation. - Antihypertensives: observe blood pressure for additive hypotensive effect. - Proton‑pump inhibitors: may alter memantine absorption; assess therapeutic response.